Search results
Showing 16 to 30 of 101 results for melanoma
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults.
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: TBC
This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)
Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Awaiting development [GID-TA10752] Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Awaiting development [GID-TA11138] Expected publication date: TBC
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.
View recommendations for IPG446Show all sections
Sections for IPG446
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)
Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.
View recommendations for IPG784Show all sections
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.